Abstract | BACKGROUND: METHODS: RESULTS: The average cost of CRS and HIPEC per patient was S$83,680.26, and the median overall survival period was 47 months. The calculated cost per life year attained for a patient who underwent CRS and HIPEC was S$21,365.19 per life year. In comparison, the average cost of palliative chemotherapy was S$44,478.87, with a median overall survival of 9 months, and the calculated cost per life year attained for a patient in this treatment group was S$59,305.16 per life year. CONCLUSION: The findings show that CRS and HIPEC results in prolonged survival for selected patients with colorectal peritoneal carcinomatosis and a lower cost per life year attained than for the traditionally used palliative chemotherapy. It should logically be the preferred treatment of choice for selected patients with colorectal peritoneal metastasis.
|
Authors | Z J Lee, S L Chia, G Tan, K C Soo, C C M Teo |
Journal | Annals of surgical oncology
(Ann Surg Oncol)
Vol. 25
Issue 8
Pg. 2340-2346
(Aug 2018)
ISSN: 1534-4681 [Electronic] United States |
PMID | 29948417
(Publication Type: Journal Article)
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Chemotherapy, Cancer, Regional Perfusion
(economics)
- Colorectal Neoplasms
(economics, pathology, therapy)
- Combined Modality Therapy
- Cost-Benefit Analysis
- Cytoreduction Surgical Procedures
(economics)
- Disease Management
- Female
- Follow-Up Studies
- Humans
- Hyperthermia, Induced
(economics)
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(economics, pathology, therapy)
- Peritoneal Neoplasms
(economics, pathology, therapy)
- Prognosis
- Retrospective Studies
- Survival Rate
|